Acute tubular necrosis is damage and necrosis of the renal tubule epithelial cells, usually caused by ischemia or nephrotoxic drugs. It presents with muddy brown casts or renal tubular cells in the urine and increased creatinine and BUN. Management involves treating the underlying cause, stopping nephrotoxic drugs, managing fluid balance and electrolyte abnormalities, and considering dialysis for refractory complications like fluid overload or uremia. Prognosis depends on the severity of the initial injury and development of complications.
Acute Kidney Injury epidemiology, pathophysiology and management based on current evidence. The presentation is suitable for internal medicine trainees and nephrology fellows.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acute Kidney Injury epidemiology, pathophysiology and management based on current evidence. The presentation is suitable for internal medicine trainees and nephrology fellows.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
1. Interns: Dr Parker, Dr Lakman, Dr Martin, Dr Thusi
Acute Tubular Necrosis
Presented by N4a- Internal Medicine
Consultant: Dr. P Guruvadu
MO/Reg: Dr Deenadayalu, Dr Ghobozi, Dr Moodley
2. Acute Tubular Necrosis (ATN)
Definition
Acute tubular necrosis is damage and necrosis of the
epithelial cells of the renal tubules. It is the most common
cause of Acute kidney injury (Intrinsic).
3. Causes
Ischemic-Induced Acute Tubular Necrosis
• Any factor that leads to prerenal azotemia can lead to ischemic acute tubular
necrosis.
• Some common causes include hypovolemic states such as diarrhea, vomiting,
bleeding, dehydration, burns, renal losses via diuretics or osmotic diuresis.
• Edematous states such as heart failure and cirrhosis cause reduced kidney
perfusion.
5. Causes cont
Sepsis-Induced Acute Tubular Necrosis
• Sepsis also plays a role in causing acute tubular necrosis because of systemic
hypotension and renal hypoperfusion.
• Other mechanisms that are incompletely understood include endotoxemia
leading to AKI by renal vasoconstriction and the release of
inflammatory cytokines causing enhanced secretion of reactive oxygen
species and leading to renal injury.
6. Pathophysiology
Made simple
• Damage to the kidney cells occurs due to ischaemia
or toxins.
• Decreased GFR leading to 3 possible mechanisms of
injury to the renal tubular epithelial cells:
• Afferent arteriolar vasoconstriction in response to
tubuloglomerular feedback
• Backleak of glomerular filtrate
• Tubular obstruction
• The epithelial cells have the ability to regenerate
making acute tubular necrosis reversible.
• It usually takes 7-21 days to recover.
7. Clinical Picture
Variable depending on clinical states
• Physical examination findings are often unremarkable AKI may be incidentally
detected on routine laboratory studies.
• Hypovolemia:
• Dizziness Fatigue Confusion Decreased urine output ( oliguria) Hypotension
Tachycardia Poor skin turgor Dry mucous membranes
• Hypervolemia/fluid overload
• Dyspnea Abdominal distension Swelling in the extremities Edema Crackles
• Ascites Pleural effusion Elevated jugular venous pressure (JVP) S3 heart sound
8. Investigations
Urine Analysis + Microscopy
• In prerenal disease, the UA microscopy is normal or may contain hyaline
casts.
• Shows muddy brown casts or renal tubular epithelial cells secondary to the
sloughing of tubular cells into the lumen due to ischemia or toxic injury.
10. Investigations Cont
• ABG- if metabolic acidosis ➡ may signify hypoperfusion
• The FBC may reveal anemia. Erythropoietin production is decreased in AKI, and dysfunctional platelets (from uraemia) ➡ bleeding
more likely.
• Measurement of fluid balances and urine output and daily measurement of creatinine and electrolytes *** Look at the Fluid charts ***
• Initiating, maintenance and recovery phases.
• The BUN and serum creatinine concentrations are increased in AKI
• We may then use these values for AKI staging
• CXR - If fluid overloaded ➡ may show pleural effusion, Kerley lines, cardiomegaly, interstitial edema etc
• U/S
• Doppler - Renal Artery Stenosis
• Kidney Stones / Obstruction
• BPH in men
12. Management
• The mainstay of management is the prevention of acute tubular necrosis by identifying the patients undergoing high-risk
procedures and having comorbidities such as diabetes mellitus, heart failure, advanced malignancy, atherosclerosis, and CKD
that can potentiate the effects of acute tubular necrosis aka treating the underlying cause
• ABCs, Glucose, IV Line access
• ECG - Hyperk ( Tall T waves , Prolonged PR waves , Widened QRS)
• Stopping/Cessation of Nephrotoxic Drugs (Genta /NSAIDS etc )
• ACEI Inhibitors should be used with caution as they reduce systemic resistance
• Volume overloaded- NaCL restriction, Diuretics
• Treating any Electrolyte disturbances :
• HyperK -IV Ca Glu, K Shift
• Hypo Na - Free water restriction
• Metabolic Acidosis - Sodium Bicarb
13. Management Cont
Dialysis -Possible indications
• Acidosis refractory to IV bicarbonate.
• Electrolyte abnormalities (typically diuresis-refractory hyperkalemia).
• Fluid overload refractory to diuretics.
• Uremic symptoms.
• Early versus late initiation of dialysis remains controversial. The best
indication for earlier dialysis may be a patient who is progressively
accumulating fluid and developing severe volume overload. As
discussed above, even in the absence of frank pulmonary edema,
systemic congestion may directly harm the kidneys, perpetuating
renal dysfunction.
A- Acidosis
E- Electrolyte
emergencies
(hyperkalemia)
I- Intoxication with
dialyzable toxins
(ethylene glycol)
O- Overloaded with
volume
U- Uremia
14. Complications
• Complications related to acute tubular necrosis are the same as related to
AKI, which include acid-base and electrolyte disturbances such as
hypocalcemia, hyperkalemia related to metabolic acidosis, and
hyperphosphatemia.
• Volume overload is related to anuria or oliguria.
• Uremic complications lead to pericarditis, bleeding diathesis, altered mental
status, seizures, coma and ultimately death.
15. Prognosis
• The mortality in patients, depends on the underlying condition that leads to
ATN .
• Some factors that lead to poor survival in such patients include oliguria, poor
nutritional status, male gender, the need for mechanical ventilation, stroke,
seizures, and acute myocardial infarction.
• The mortality rate is higher in oliguric patients than in non-oliguric patients
signifying the amount of damage done leading to necrosis.
• Mortality is high (about 60%) in sepsis and surgical patients, causing multiple
organ failure.
16. Summary
ATN Is caused by : Ischemia / Nephrotoxic Drugs
• Shock Sepsis Dehydration
• Radiology contrast dye , Gentamycin, NSAIDS
UA - Muddy Brown Casts, TECs
U&E- identifies staging and therefore Kidney Function
Management
• Treat the underlying cause
• IV fluids - Ensure you choosing the correct type for your pt
• Stop nephrotoxic medications
• Treat complications
• Monitor urine output, especially in patients who are at risk for renal failure, and follow the BUN and creatinine.
17. Case study
• John C Ena, 32 yo M, Prisoner
• #HPT #Prev Covid Pneumo #RVD Neg
• #Presented w Infected Endocarditis.
• Started on IVI Ampicillin , Gentamicin,ACEI
and failure treatment -Lasix enalapril.
• Cr - 74 mmol, Urea - 7.3 mmol
• Now - Pleural effusion Elevated JVP, S3
heart sound
• Current Cr 350⬆, Urea 21⬆
• Na 126 ⬇ , K 6.2 ⬆
1. What’s the first/initial management plan for this patient?
A. Continue and lower dose of Antibiotics.
B. Request renal U/S
C. Cease all nephrotoxic drugs
D. DIALYSIS now.
2. What is your current supposition of diagnosis?
A. AKI.
B. CKD.
C. Rhabdomyolysis
D. UTI.
You then request an ECG that shows no Tall T waves nor prolonged PR
waves.
3. You then request a UA, that shows Muddy Brown Casts. What is the most
likely diagnosis?
A. Glomerular Nephritis.
B. ATN.
C. AIN.
D. Rhabdomyolysis.
4. Is this patient Indicated for emergency Dialysis?
A. Yes
B. No
18. References
• Pubmed:Early versus late initiation of renal replacement therapy in patients
with acute kidney injury-a systematic review & meta-analysis of randomized
controlled trials
• Pubmed:Acute kidney injury: Preventing acute kidney injury through
nephrotoxin management
• Pubmed:Acute Tubular Necrosis
• Medscape:Acute Tubular Necrosis Treatment & Management
• Images: https://zerotofinals.com/medicine/renal/atn/